Abstract
Thiol-containing antioxidant systems play an important role in regulating cellular redox homeostasis. Several anti-cancer agents act by targeting these systems by inducing the production of reactive oxygen species (ROS). Our earlier studies have shown that Eriocalyxin B (EriB), a diterpenoid isolated from Isodon eriocalyx, possesses anti-pancreatic tumour activities in vitro and in vivo. The present study further demonstrated that only thiol-containing antioxidants, N-acetylcysteine (NAC) or dithiothreitol (DTT), inhibited EriB-induced cytotoxicity and apoptosis. EriB suppressed the glutathione and thioredoxin antioxidant systems, thus increasing the intracellular ROS levels and regulating the MAPK, NFκB pathways. Treatment with EriB depleted the intracellular thiol-containing proteins in CAPAN-2 cells. In vivo studies also showed that EriB treatment (2.5 mg/kg) reduced the pancreatic tumour weights significantly in nude mice with increased superoxide levels. Taken together, our results shed important new light on the molecular mechanisms of EriB acting as an apoptogenic agent and its therapeutic potential for pancreatic cancer.
Keywords: Apoptosis, eriocalyxin B, pancreatic cancer, reactive oxygen species, thiols.
Current Molecular Medicine
Title:Eriocalyxin B-Induced Apoptosis in Pancreatic Adenocarcinoma Cells Through Thiol-Containing Antioxidant Systems and Downstream Signalling Pathways
Volume: 14 Issue: 5
Author(s): L. Li, G.G.L. Yue, J.X. Pu, H.D. Sun, K.P. Fung, P.C. Leung, Q.B. Han, C.B.S. Lau and P.S. Leung
Affiliation:
Keywords: Apoptosis, eriocalyxin B, pancreatic cancer, reactive oxygen species, thiols.
Abstract: Thiol-containing antioxidant systems play an important role in regulating cellular redox homeostasis. Several anti-cancer agents act by targeting these systems by inducing the production of reactive oxygen species (ROS). Our earlier studies have shown that Eriocalyxin B (EriB), a diterpenoid isolated from Isodon eriocalyx, possesses anti-pancreatic tumour activities in vitro and in vivo. The present study further demonstrated that only thiol-containing antioxidants, N-acetylcysteine (NAC) or dithiothreitol (DTT), inhibited EriB-induced cytotoxicity and apoptosis. EriB suppressed the glutathione and thioredoxin antioxidant systems, thus increasing the intracellular ROS levels and regulating the MAPK, NFκB pathways. Treatment with EriB depleted the intracellular thiol-containing proteins in CAPAN-2 cells. In vivo studies also showed that EriB treatment (2.5 mg/kg) reduced the pancreatic tumour weights significantly in nude mice with increased superoxide levels. Taken together, our results shed important new light on the molecular mechanisms of EriB acting as an apoptogenic agent and its therapeutic potential for pancreatic cancer.
Export Options
About this article
Cite this article as:
Li L., Yue G.G.L., Pu J.X., Sun H.D., Fung K.P., Leung P.C., Han Q.B., Lau C.B.S. and Leung P.S., Eriocalyxin B-Induced Apoptosis in Pancreatic Adenocarcinoma Cells Through Thiol-Containing Antioxidant Systems and Downstream Signalling Pathways, Current Molecular Medicine 2014; 14 (5) . https://dx.doi.org/10.2174/1566524014666140603102459
DOI https://dx.doi.org/10.2174/1566524014666140603102459 |
Print ISSN 1566-5240 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5666 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Engineered Inorganic Nanoparticles for Drug Delivery Applications
Current Drug Metabolism Epigenetic Regulation of Cytochrome P450 Enzymes and Clinical Implication
Current Drug Metabolism Novel Therapeutic Strategies in Infection and Cancer Management
Current Aging Science Natural Products as Promising Antitumoral Agents in Breast Cancer: Mechanisms of Action and Molecular Targets.
Mini-Reviews in Medicinal Chemistry Anti-Epidermal Growth Factor Receptor Antibodies in the Treatment of Metastatic Colorectal Cancer
Recent Patents on Anti-Cancer Drug Discovery Oncolytic Viruses: Programmable Tumour Hunters
Current Gene Therapy Dasatinib: An Anti-Tumour Agent via Src Inhibition
Current Drug Targets Aberrant Regulation of Translation Initiation in Tumorigenesis
Current Molecular Medicine Bcl-2 Inhibitors: Emerging Drugs in Cancer Therapy
Current Medicinal Chemistry Current View on the Mechanism of Action of Perifosine in Cancer
Anti-Cancer Agents in Medicinal Chemistry Src Kinase Inhibitors: An Update on Patented Compounds
Current Medicinal Chemistry Detection of Predictive Markers for Therapeutic Stratification of Salivary Glands Tumors
Current Drug Targets Functional Role of miR-34 Family in Human Cancer
Current Drug Targets Modulation of DNA Damage Checkpoint; Patenting and Possible Application for Cancer Medicine
Recent Patents on DNA & Gene Sequences Beam Commissioning Data Acquisition for the Iris Variable Aperture Collimator of CyberKnife VSI
Neuroscience and Biomedical Engineering (Discontinued) Dietary Manipulation of Precursor Polyunsaturated Fatty Acids Modulates Eicosanoid and Endocannabinoid Synthesis: A Potential Tool to Control Tumor Development
Current Nutrition & Food Science Epigenetic Regulators Governing Cancer Stem Cells and Epithelial- Mesenchymal Transition in Oral Squamous Cell Carcinoma
Current Stem Cell Research & Therapy Merkel Cell Carcinoma: Epidemiology, Clinical Presentations, Histology, Polyomavirus Involvement, and Management
Current Cancer Therapy Reviews Metallothioneins and Platinum(II) Anti-Tumor Compounds
Current Medicinal Chemistry Critical Review of Malondialdehyde Analysis in Biological Samples
Current Pharmaceutical Analysis